Will Key Drugs Maintain Momentum for Novartis in Q2 Earnings?

• click to rate

  Posted by Two Blokes Jul 15 - Filed in Stock - 2 views
  
  Strong sales of Entresto, Kisqali, Kesimpta, Leqvio and Scemblix have likely benefited NVS' Q2 performance and offset the impact of generics.